U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06959615) titled 'A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration' on April 28.
Brief Summary: This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The study consists of 2 phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.
Study Start Date: Nov. 22, 2024
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: JAB-23E73
Administered orally
DRUG: JAB-23E73
Ad...